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Abstract. The clinical significance of hyperprolactinaemia in uraemic patients is uncertain and discrepancies between immunoactivity and biological activity of serum hPRL have been reported. We have modified the Nb2 cell bioassay to improve specificity for hPRL and used this assay to measure hPRL bioactivity in sera from 26 uraemic patients and 40 control subjects. Seventeen patients were receiving regular haemodialysis and 9 continuous ambulatory peritoneal dialysis. Levels of hPRL bioactivity were compared with hPRL immunoactivity measured by RIA (PRL-RIA) and by immunoradiometric assay (PRL-IRMA). Serum hPRL levels measured by all three assays were significantly elevated in uraemic patients compared with control subjects (P< 0.001) . The immunoradiometric method gave significantly lower results than RIA in control subjects but not in uraemic patients (P< 0.05). There was no significant difference in mean ratio of hPRL bioactivity to PRL-RIA between patients and control subjects (1.18 \ m=+-\ 0.05 vs 1.11 \ m=+-\ 0.03, mean \ m=+-\ sem). The ratio of hPRL bioactivity to PRL-IRMA was slightly decreased in uraemic patients compared with controls (P = 0.05). Serum (Lim et al. 1979; Holdsworth et al. 1978) . Uraemic hypogonadism, which is almost universal in dialysed patients, is multifactorial, with evidence of defects at hypothalamic, pituitary and gonadal levels (Handelsman 1985; Gomez et al. 1980; Holdsworth et al. 1977; Lim et al. 1980 ).
The role of hyper-prolactinaemia is uncertain, and it has been suggested that the high levels of hPRL detected by RIA may not represent intact, fully biologically active hormone (Mooradian et al. 1985) .
We have modified the Nb2 rat lymphoma cell bioassay for serum lactogens (Tanaka et al. 1980) by the use of monoclonal antibodies to make the assay specific for hPRL bioactivity, and used it to study sera from uraemic patients receiving treatment with HD or CAPD. The precision and reproducibility of the Nb2 bioassay, modified in this way, are comparable with those of immunoassay (Smith et al. 1988 ).
Patients and Methods

Patients
We studied 26 patients with ESRF who had been receiv¬ ing regular dialysis for at least 3 months at the time of the study and were in good general health. Seventeen pa¬ tients (7 men, 10 women) were treated with HD three times weekly in the Renal Unit and 9 patients (7 men, 2 women) were treated with CAPD. No patient was taking drugs known to affect PRL secretion, but 5 patients were taking low-dose prednisolone (< 10 
Bioassay procotol
The bioassay was carried out as described previously (Smith et al. 1988 (Bohnet & Riley 1981) , whereas the H2 anta¬ gonist cimetidine does cause a rise in serum hPRL levels (Carlson & Ippoliti 1977; Bohnet et al. 1978 (Suh & Frantz 1974; Guyda 1975; Gamier et al. 1978) with two or three immunoreac¬ tive forms usually being detected. Monomeric (23K) hPRL is the predominant form in unstimulated normal subjects.
Evidence for reduced biological activity of hPRL in uraemia comes from a study by Mooradian et al. (1985) . They found significantly lower levels of total serum lactogens (measured using the Nb2 assay) than of immunoactive hPRL (measured by RIA) 
